- Home
- TPIC vs THTX Comparison
TPIC vs THTX Comparison
Compare TPIC & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- THTX
- Stock Information
- Founded
- TPIC 1968
- THTX 1993
- Country
- TPIC United States
- THTX Canada
- Employees
- TPIC N/A
- THTX N/A
- Industry
- TPIC Industrial Machinery/Components
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- TPIC Industrials
- THTX Health Care
- Exchange
- TPIC Nasdaq
- THTX Nasdaq
- Market Cap
- TPIC 65.6M
- THTX 71.3M
- IPO Year
- TPIC 2016
- THTX N/A
- Fundamental
- Price
- TPIC $0.81
- THTX $1.40
- Analyst Decision
- TPIC Hold
- THTX Hold
- Analyst Count
- TPIC 6
- THTX 1
- Target Price
- TPIC $1.86
- THTX N/A
- AVG Volume (30 Days)
- TPIC 890.0K
- THTX 2.9M
- Earning Date
- TPIC 05-01-2025
- THTX 04-09-2025
- Dividend Yield
- TPIC N/A
- THTX N/A
- EPS Growth
- TPIC N/A
- THTX N/A
- EPS
- TPIC N/A
- THTX N/A
- Revenue
- TPIC $1,331,131,000.00
- THTX $85,866,000.00
- Revenue This Year
- TPIC $9.08
- THTX $3.57
- Revenue Next Year
- TPIC $9.44
- THTX $7.73
- P/E Ratio
- TPIC N/A
- THTX N/A
- Revenue Growth
- TPIC N/A
- THTX 5.02
- 52 Week Low
- TPIC $0.73
- THTX $1.08
- 52 Week High
- TPIC $5.75
- THTX $2.18
- Technical
- Relative Strength Index (RSI)
- TPIC 37.74
- THTX 40.24
- Support Level
- TPIC $0.79
- THTX $1.51
- Resistance Level
- TPIC $0.87
- THTX $2.12
- Average True Range (ATR)
- TPIC 0.11
- THTX 0.12
- MACD
- TPIC -0.00
- THTX -0.01
- Stochastic Oscillator
- TPIC 14.84
- THTX 11.11
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.